|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
SciClone Pharmaceuticals
| | | Phone: | (650) 358-3456 | Fax: | (650) 358-3469 | Year Established: | 1989 | Main Contact: | Friedhelm Blobel, Ph.D., President & CEO | | Other Contacts: | Lan Xie, VP, Finance & CFO, China Operations Raymond A. Low, VP, Finance and Controller Carey Chern, General Counsel Wilson W. Cheung, CFO Hong Zhao, CEO, China Operations
| | Company Description | SciClone Pharmaceuticals, a subsidiary of Holdco, is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as an immune system enhancer, according to the local regulatory approvals. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead®, a novel treatment for liver cancer. Through its promotion business with pharmaceutical partners, SciClone also markets multiple branded products in China which are therapeutically differentiated.
On Oct. 13, 2017, SciClone and a consortium consisting of GL Capital Management, Bank of China Group, Ascendent Capital and Boying announced completion of the merger between Silver Biotech Investment Limited. As a result, the Company ceased to be a publicly traded company and became a subsidiary of Holdco. | |
|
|
|
|
|